Navigation Links
Adeona to Host First Quarter 2011 Investor Conference Call
Date:5/10/2011

ANN ARBOR, Mich., May 10, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its 1st quarter 2011 investor conference call on Tuesday, May 17, 2011, at 1:00pm EDT. James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer, will host the call.  

The Company will be joined by special guest, Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, and Lead Principal Investigator of the multi-center clinical trial evaluating Adeona's Trimesta™ (oral estriol) drug candidate for multiple sclerosis (MS) in women. Dr. Voskuhl is the investigator who discovered that the female sex hormone, estriol, could suppress MS-like symptoms in a mouse model of the disease.  This preclinical research led to a 10-patient clinical study that showed an 82% decrease in brain lesions over a six month period.  This clinical study was followed by a 150-patient, randomized, double-blind, placebo-controlled clinical trial of Trimesta that is currently underway at 15 centers in the United States. Dr. Voskuhl's preclinical and clinical work has been scientifically reviewed and awarded over $8 million in grant funding by organizations such as the National Institutes of Health, the National Multiple Sclerosis Society and other third party groups. In addition to providing an update of the Trimesta clinical trial, Dr. Voskuhl will share insights into her proposed new mechanism to treat MS patients and will take questions about her research.

Interested parties should call toll free 1-800-860-2442 (U.S.) or 1-866-605-3852 (Canada), or from outside North America +1 412-858-4600, fifteen minutes before the start of the call to register and identify themselves as registrants of the 'Adeona' Conference Call. Any registered caller on the toll free line may ask to be placed in the queue for the Question & Answer session. The call will be simulcast on the web at http://www.videonewswire.com/event.asp?id=79592. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL (http://www.videonewswire.com/event.asp?id=79592) for 30 days after the call.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing, or has partnered the development of, the following product candidates: a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and drugs to treat multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding new mechanisms to treat MS patients. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, the failure of the new mechanisms to be successful in treating MS, a lack of funding despite the recent grants, our failure to successfully commercialize a new oral therapy for multiple sclerosis, the availability of additional financial and other resources and the allocation of resources among different potential uses, a failure of our clinical trial to complete enrollment in the anticipated time period or to achieve desired results, our ability to initiate additional clinical programs for multiple sclerosis and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
2. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
3. Adeona to Host Conference Call
4. Adeona to Raise $3.5 Million in Registered Direct Offering
5. Adeona Reports 2010 Year End Financial Results
6. Adeona to Host 2010 Year End Investor Conference Call
7. Adeonas Multiple Sclerosis Trial Receives $409,426 Grant
8. Adeona Receives Excellence in Science & Technology Award
9. Adeona Appoints George J. Brewer, M.D., Senior Vice President of Research & Development
10. Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development
11. Adeonas Alzheimers Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurologys 63rd Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts in 2017, estimates ... generate $655 million in taxes on retail sales. Out of this ... Washington State,s 37% cannabis retail tax rate. ... that are applied on all retail sales. By 2020, tax revenues ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
Breaking Medicine Technology:
(Date:3/27/2017)... California (PRWEB) , ... March 27, 2017 , ... The ... to its customers. First National Capital has added 10 new sales professionals over the ... its sales positions by 15 additional new hires over the course of 2017. ...
(Date:3/27/2017)... Mt. Angel, Oregon (PRWEB) , ... March 27, ... ... supplements company, is pleased to announce the launch of a months-long rebranding effort. ... exciting new formulations. , “Through focus group discussions and market research, we learned ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center ... Monday, April 3rd to commemorate the two-year anniversary of the facility. The event ... celebrate two great years while also familiarizing themselves with the facility. , In ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion ... renovations is also on the rise. Per a 2017 report, 13% of all households ... to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin Harper ... prestigious award honoring the top influencers on RealSelf—the most trusted online destination to ... and clinics. , In 2016, more than 82 million people visited RealSelf to ...
Breaking Medicine News(10 mins):